Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15262204 | 0.81 | PDE3B (0.32) | PDE3BPDE3A | |
| SCHEMBL24156076 | 0.76 | PIK3CD (0.40) | PDE3BPDE3APIK3CDPIK3CAPIK3CB | |
| SCHEMBL24270120 | 0.75 | PDE3B (0.36) | PDE3BPDE3APIK3CDPIK3CAPIK3CB | |
| SCHEMBL12077642 | 0.73 | MAPK14 (0.40) | PDE3BPDE3APIK3CDPIK3CAPIK3CB | |
| SCHEMBL4772120 | 0.73 | HTR2C (0.46) | PDE3BPDE3APIK3CDPIK3CAPIK3CB | |
| SCHEMBL14183094 | 0.73 | MAPK14 (0.48) | PDE3BPDE3APIK3CDPIK3CAPIK3CB | |
| SCHEMBL26560458 | 0.72 | HTR1D (0.43) | PDE3BPDE3APIK3CDPIK3CAPIK3CB | |
| SCHEMBL23956483 | 0.71 | HTR1D (0.42) | PDE3BPDE3APIK3CDPIK3CAPIK3CB | |
| SCHEMBL932928 | 0.70 | PIK3CD (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGMAPK14 | |
| SCHEMBL24270135 | 0.70 | PIK3CD (0.35) | PDE3BPDE3APIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831053-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2831064-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-17 | — | — | EP | disclosed |
| EP-2831064-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-17 | — | — | EP | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2831064-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| EP-2831053-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | disclosed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144097-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| WO-2013051639-A1 | PYRAZOLOQUINOLINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | PDE3B 3/4885PDE3A 2/4885PIK3CD 1155/4885 |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPR55, GPR52 | PDE3B 2736/4885PDE3A 2106/4885PIK3CD 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.